Floatz Rating
BB69/100
Confidence
Indicative
Sponsor
VA Office of Research and Development
Modality
Small molecule
Development Phase
Phase 4 / Approved
Status
Dormant
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
54High confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT00470262CT.gov Effects of PPAR Ligands on Ectopic Fat Accumulation and Inflammation | — | Completed | — | — | — |
NCT00579813CT.gov Mechanisms Underlying Metabolic Syndrome in Obesity | — | Completed | — | — | — |
NCT00352287CT.gov Study to Determine the Effects of Human Growth Hormone and Pioglitazone in Overweight, Prediabetic Adults | — | Completed | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
95High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Prediabetes Syndrome
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Pioglitazone (this asset) | VA Office of Research and Development | Approved | BB · 69 |
| Metformin | Yu Chen | P4 | A |
| Liraglutide | Woman's | P4 | BBB |
| Semaglutide | Esbjerg Hospital - University Hospital of Southern Denmark | P4 | BBB |
| Exenatide | RenJi Hospital | P4 | BBB |
| Empagliflozin | The University of Texas Health Science Center at San Antonio | P4 | BBB |
| Sitagliptin | Vanderbilt University Medical Center | P4 | BB |
| Dapagliflozin | Centro Medico Nacional Siglo XXI IMSS | P2/3 | BB |
| Saxagliptin | The University of Texas Health Science Center, Houston | P4 | BB |
+42 more in the Prediabetes Syndrome cohort
Other indications for Pioglitazone
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Diabetes Mellitus | — | P4 | BBB · 79 |
| Metabolic Dysfunction-Associated Steatohepatitis | — | P4 | BBB · 75 |
| Abdominal Obesity-Metabolic Syndrome | — | P4 | BBB · 73 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Pioglitazone in Prediabetes Syndrome. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/pioglitazone-prediabetes-syndrome
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →